/	OIPE
PA	AUG 2 6 2002 E
(E)	PADEMARK

DTOGRECT PCT/PTO 26 AUG 2007

Please type a plus sign (+) inside this box

+ Approved for use through 09/30/2000

Patent and Trademark Office: U.S. DEPARTMENT

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
or required to respond to a collection of information unless the design of the collection of the collec

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Number	10/089,958				
TRANSMITTA	\L	Filing Date	April 4, 2002				
FORM		First Named Inventor	John Hughes				
(to be used for all correspondence after ini	itial filing)	Group Art Unit					
		Examiner Name					
Total Number of Pages in This Submission	on	Attorney Docket Number	A0000005/1-01-MG				
	ENCLOS	SURES (check all that app	oly)				
Fee Transmittal Form Fee Attached Amendment / Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application	Drawing Licensin Petition and Acc Petition Provisio Change Address Termina Small E	ng-related Papers Routing Slip (PTO/SB/69) companying Petition to Convert to a nal Application of Attorney, Revocation of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Additional Enclosure(s) (please identify below): Return Postcard AND 7 2003				
Response to Missing Parts under 37 CFR 1.52 or 1.53			2900				
SIGNATURE	OF APPLI	CANT, ATTORNEY, OR					
Firm or Individual name Mehdi Ganjeizadeh Signature	zerade	<i></i>					
Date 8/22/02							
	CERTIFIC	ATE OF MAILING					
I hereby certify that this correspondence is envelope addressed to: Assistant Commission	being deposi	ted with the United States Poents, Washington, D.C. 2023	ostal Service as <u>first class mail in an</u> 11 on this date: 8/22/02				
Typed or printed name Cindy Malocha			9/22/02				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

				<u>.</u>
(Rev. 8-32) COMM	DEPARTMENT OF MERCE PATENT AND DEMARK OFFICE	ATTY. DOCKET NO. A0000005/2-01-MG	SERIAL NO. 10/089,958	c∴,
AUG 2 6 2002 STATEMENT B		APPLICANT JOHN HUGHES, ET AL.		
(Use several shee	ets if necessary)	FILING DATE April 4, 2002	GROUP	
RADEMA				

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5	5	1	0	3	8	1	4/23/96	Pande	514	561	_
	 5	0	2	5	0	3	5	6/18/91	Wallace	514	530	
	 5	7	9	2	7	9	6	8/11/98	Woodruff et al.	514	561	
	Π	Γ			Γ							

FOREIGN PATENT DOCUMENTS

	DO	DOCUMENT NUMBER						DATE		COUNTRY		SUBCLASS	TRANSLATION	
												1	YES	NO
 	9	8	2	4	4	3	9	11.06.98	wo					х
	9	8	1	5	2	7	7	16.04.98	wo					х
	Τ													
												1		ļ

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

	PCT International Search Report, PCT/EP00/10084
	Field et al., "Involvement of the Central Tachykinin NK1 Receptor during Maintenance of Mechanical Hypersensitivity Induced by Diabetes in the Rat", The Journal of Pharmacology and Experimental Therapeutics, Vol. 285, No. 3, 1998, pages 1226-1232
	McLean et al., "CP-99,994, a nonpeptide antagonist of the tachykinin NK1 receptor", Regulatory Peptides, Vol. 45, 1993, pages 329-331
	Bryans and Wustrow, "3-Substituted GABA Analogs with Central Nervous System Activity: A Review", Medicinal Research Reviews, Vol. 19, No. 2, 1999, pages 149-177
	Field et al., "GABAPENTIN AND THE NK1 RECEPTOR ANTAGONIST CI-1021 ACT SYNERGISTICALLY TO BLOCK ALLODYNIA INDUCED IN A RAT MODEL OF NEUROPATHIC PAIN", British Journal of Pharmacology, Vol. 129, proceedings Supplement, 2000, page 79P
	<u> </u>
	166 20
EVAMINED	DATE CONSIDERED SO TO
EXAMINER	DATE CONSIDERED 8

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.